Aspen Aerogels Inc (ASPN) concluded trading on Thursday at a closing price of $4.31, with 9.99 million shares of worth about $43.06 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -76.38% during that period and on May 08, 2025 the price saw a loss of about -24.25%. Currently the company’s common shares owned by public are about 82.04M shares, out of which, 80.64M shares are available for trading.
Stock saw a price change of -22.34% in past 5 days and over the past one month there was a price change of -14.14%. Year-to-date (YTD), ASPN shares are showing a performance of -63.72% which decreased to -83.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.80 but also hit the highest price of $33.15 during that period. The average intraday trading volume for Aspen Aerogels Inc shares is 2.00 million. The stock is currently trading -18.94% below its 20-day simple moving average (SMA20), while that difference is down -31.15% for SMA50 and it goes to -71.71% lower than SMA200.
Aspen Aerogels Inc (NYSE: ASPN) currently have 82.04M outstanding shares and institutions hold larger chunk of about 89.97% of that.
The stock has a current market capitalization of $353.87M and its 3Y-monthly beta is at 2.72. PE ratio of stock for trailing 12 months is 27.72, while it has posted earnings per share of $0.16 in the same period. Its PEG reads 0.34 and has Quick Ratio of 3.29 while making debt-to-equity ratio of 0.32. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ASPN, volatility over the week remained 6.96% while standing at 6.31% over the month.
Stock’s fiscal year EPS is expected to drop by -547.71% while it is estimated to increase by 161.56% in next year.
Coverage by TD Cowen stated Aspen Aerogels Inc (ASPN) stock as a Buy in their note to investors on March 07, 2025, suggesting a price target of $11 for the stock. On February 13, 2025, Seaport Research Partners Downgrade their recommendations, while on August 06, 2024, Barclays Initiated their ratings for the stock with a price target of $27. Stock get a Buy rating from ROTH MKM on March 06, 2024.
